Oxford BioMedica - Announcements

News / Announcements 2001

Date	Article

13 Dec 2001	Progress Made in Nerve Repair Programme - Issues of Shares to King's College London

12 Nov 2001	Positive Preclinical Results in Gene Therapy for Parkinson's Disease

15 Oct 2001	Successful Interim Phase I/II Trovax^® Results

02 Oct 2001	Termination of Collaboration with Modex Therapeutics SA

01 Aug 2001	Oxford BioMedica Interim Results for the Six Months Ended 30 June 2001

10 Jul 2001	GTAC approval for development of METXIA^® clinical program

26 Jun 2001	Oxford BioMedica Obtains Fundamental Patent for Lentiviral Gene Therapy Technology

29 May 2001	Appointment of CEO to Oxford BioMedica US Subsidiary

24 Apr 2001	Oxford BioMedica: Inclusion in the techMARK Index of the London Stock Exchange

17 Apr 2001	Admission to the Official List Results of Placing and Open Offer Results of Extraordinary General Meeting

27 Mar 2001	Oxford BioMedica Obtains Gene Therapy Patent in the USA

12 Mar 2001	Admission to the Official List. Placing to Raise £30 Million and Open Offer to Raise Up to £10 Million

13 Feb 2001	Oxford BioMedica Appoints Non-Executive Director

05 Feb 2001	Oxford BioMedica: Acquisition of Novel Technology for Nerve Regeneration and Issue of Shares

01 Feb 2001	Oxford BioMedica Acquires Access to Antibody Technology

26 Jan 2001	Oxford BioMedica Preliminary Results for the Year Ended 31 December 2000

22 Jan 2001	Oxford BioMedica Signs Agreement with American Home Products for Novel Anti-Cancer Antibody Therapy

02 Jan 2001	Oxford BioMedica Appoints Dr Peter Johnson as Chairman

02 Jan 2001	Oxford BioMedica Commences Clinical Trial of TroVax™

Website by College Hill - Life Sciences

2008

Archive

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997